PO.CL11.02 · 临床研究
癌症治疗期间的大麻使用：威斯康星州一家癌症中心癌症幸存者的大麻使用模式与认知
Cannabis use during cancer treatment: Patterns and perceptions of cannabis use among cancer survivors at a Wisconsin cancer center
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景：癌症幸存者越来越多地使用大麻产品来管理治疗相关的症状。然而，人们对他们如何看待大麻产品缓解症状的效果，或哪些障碍影响其使用知之甚少。我们旨在刻画癌症患者的大麻产品使用情况和认知。
方法：我们对UW Health/Carbone Cancer Center诊所中在过去3个月内接受过治疗的650名成年患者进行了横断面调查，应答率为54%（54名患者死亡，320名应答）。报告在被诊断为癌症后使用大麻产品的患者（n=92）符合本分析的入选条件。调查采集了人口统计学信息、使用大麻产品后感知的症状变化以及使用障碍。使用STATA和R完成了描述性分析和Kendall-Wei秩分析。
结果：应答患者的中位年龄为62岁（IQR：53-67）；51%为女性，89%为白人，34%的年收入达到10万美元或以上，50%完成了大学或技术学校教育，35%在过去一年内使用过烟草。半数患者患有转移性癌症（48%）。大多数患者在此前3个月内接受了化疗（55%）和/或放疗（54%）。患者最可能报告大麻产品改善了他们的疼痛（76%）和恶心/呕吐（76%）（表1）。患者最常报告的大麻产品使用障碍是费用（35%）和对法律风险的担忧（32%）。大多数患者赞成THC（94%）和CBD（96%）医疗用途的合法化。大多数患者很有可能或极有可能在未来使用大麻产品（66%）。
结论：在这一批诊断后使用大麻产品的威斯康星州癌症患者队列中，大多数人认为大麻产品在管理癌症症状（尤其是疼痛）方面有益。尽管报告了益处，费用和合法性仍是威斯康星州人使用大麻的障碍。
表1. 患者自我报告从大麻中获益（即症状或副作用改善）情况 症状 报告该症状的患者数 获益n(%) 疼痛 72 55(76%) 食欲不振 67 48(72%) 睡眠丧失 78 53(68%) 易怒 67 46(69%) 焦虑 70 42(60%) 恶心/呕吐 58 44(76%) 抑郁 61 30(49%) 疲乏或精力低下 78 31(40%) 头痛 51 22(43%) 神经病变 57 13(23%) 缺乏性兴趣或性活动 61 12(20%) 出汗，包括潮热或盗汗 56 6(11%)
查看英文原文 English abstract
Background:Cancer survivors increasingly use cannabis products to manage treatment-related symptoms. Yet, little is known about their perceptions of the helpfulness of cannabis products for symptom relief or what barriers shape their use. We aimed to characterize cannabis product use and perceptions among cancer patients.
Methods:We administered a cross-sectional survey to 650 adult patients at UW Health/Carbone Cancer Center clinics who had received treatment within the last 3 months, with a response rate of 54% (54 patients died, 320 responded). Patients who reported using cannabis products after being diagnosed with cancer (n=92) were eligible for this analysis. The survey captured demographics, perceived symptom change with cannabis product use, and barriers to use. Descriptive analyses and Kendall-Wei Rank were completed using STATA and R.
Results: Patients who responded had a median age of 62 (IQR: 53-67) years; 51% were women, 89% were White, 34% had an annual income of $100,000 or more, 50% had completed college or technical school, and 35% used tobacco in the past year. Half the patients had metastatic cancer (48%). Most patients received chemotherapy (55%) and/or radiation (54%) within the prior 3 months. Patients were most likely to report that cannabis products improved their pain (76%) and nausea/vomiting (76%) (Table 1). Patients' most-reported barriers to cannabis product use were cost (35%) and concern about legal risk (32%). Most patients were in favor of legalizing the medicinal use of THC (94%) and CBD (96%). Most patients were very or extremely likely to use cannabis products in the future (66%).
Conclusion:In this cohort of Wisconsin patients with cancer who used cannabis products after diagnosis, the majority perceived cannabis products to be beneficial in managing cancer symptoms, particularly pain. Despite the reported benefits, cost and legality are barriers to cannabis use among Wisconsinites.
Table 1. Patient self-report of receiving benefit (i.e., symptoms or side effects improved) from can Symptom Number of patients reporting this symptom Benefit n (%) Pain 72 55 (76%) Lack of appetite 67 48 (72%) Sleep loss 78 53 (68%) Irritability 67 46 (69%) Anxiety 70 42 (60%) Nausea/vomiting 58 44 (76%) Depression 61 30 (49%) Fatigue or low energy 78 31 (40%) Headache 51 22 (43%) Neuropathy 57 13 (23%) Lack of sexual interest or activity 61 12 (20%) Sweating, including hot flashes or night sweats 56 6 (11%)
利益披露 Disclosure
A. C. Reddy, None..
J. Dykema, None..
B. Chewning, None..
K. Kwekkeboom, None..
H. Neuman, None.